Update on the emerging role of telavancin in hospital-acquired infections

Nnedu, Obinna N. and Pankey, George A. (2015) Update on the emerging role of telavancin in hospital-acquired infections. Therapeutics and Clinical Risk Management, 11 605-610. doi:10.2147/TCRM.S57376

Author Nnedu, Obinna N.
Pankey, George A.
Title Update on the emerging role of telavancin in hospital-acquired infections
Journal name Therapeutics and Clinical Risk Management   Check publisher's open access policy
ISSN 1178-203X
Publication date 2015-04-13
Sub-type Article (original research)
DOI 10.2147/TCRM.S57376
Open Access Status DOI
Volume 11
Start page 605
End page 610
Total pages 6
Place of publication Macclesfield, United Kingdom
Publisher Dove Medical Press
Collection year 2016
Language eng
Formatted abstract
Telavancin is a lipoglycopeptide that has activity against gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant enterococci. It has been approved by the US Food and Drug Administration (FDA) for complicated skin and skin structure infections and hospital-acquired pneumonia. There is a need for more clinical studies to determine the role of telavancin in treating bacteremia and prosthetic device infections. In this review, we discuss the published data on the use of telavancin in treating hospital-acquired infections and provide an update on new research.
Keyword Linezolid
Staphylococcus aureus
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 10 May 2015, 01:20:18 EST by System User on behalf of Scholarly Communication and Digitisation Service